Scaling up biohybrid robots has been difficult due to the weak contractile force of lab-grown muscles, the risk of necrosis ...

WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...

Correspondence to Dr Kimberly G Harmon, Hall Health Sports Medicine Clinic, Box 354410, University of Washington, Seattle, WA 98195, USA; kharmon{at}u.washington.edu If you wish to reuse any or all of ...

Thick muscle tissue, which is needed to move larger limbs, is difficult to grow in the lab, as it suffers from necrosis. This ...

WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in ...

The disease can remain asymptomatic for a long time, but at worst, it can ultimately lead to necrosis and amputation. "Muscle microvasculature responds to hypoxia by dilating in an attempt to ...

Clostridial myositis, also known as gas gangrene, malignant edema, or clostridial myonecrosis, is an infection of skeletal ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

Cardiac enzymes are released into the circulation when myocardial necrosis occurs, as seen in myocardial infarction. Myoglobin is released into circulation with any damage to muscle tissue ...

Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.